Keith Dredge

Summary

Affiliation: St George's Hospital Medical School
Country: UK

Publications

  1. ncbi request reprint Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
    Keith Dredge
    Division of Oncology, Department of Oncology, Gastroenterology, Endocrinology, and Metabolism, St George s Hospital Medical School, Cranmer Terrace, Tooting, London, United Kingdom SW17 0RE
    J Immunol 168:4914-9. 2002
  2. ncbi request reprint Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, U K
    Cancer Immunol Immunother 51:521-31. 2002
  3. ncbi request reprint Recent developments in antiangiogenic therapy
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Jenner Wing, Cranmer Terrace, Tooting SW17 0RE, London, UK
    Expert Opin Biol Ther 2:953-66. 2002
  4. ncbi request reprint Immunological effects of thalidomide and its chemical and functional analogs
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Cranmer Terrace, London, UK SW17 ORE
    Crit Rev Immunol 22:425-37. 2002
  5. ncbi request reprint Thalidomide analogs as emerging anti-cancer drugs
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, London, UK
    Anticancer Drugs 14:331-5. 2003
  6. ncbi request reprint Angiogenesis inhibitors in cancer therapy
    Keith Dredge
    Division of Oncology, Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Tooting, London, SW17 0RE, UK
    Curr Opin Investig Drugs 4:667-74. 2003
  7. ncbi request reprint Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents
    J Blake Marriott
    Division of Oncology, Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London, UK
    Curr Drug Targets Immune Endocr Metabol Disord 3:181-6. 2003
  8. doi request reprint The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
    Christine Galustian
    Department of Oncology, St Georges University of London, Cranmer Terrace, Tooting, London, UK
    Cancer Immunol Immunother 58:1033-45. 2009
  9. ncbi request reprint Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
    Keith Dredge
    Department of Cellular and Molecular Medicine, St George s Hospital Medical School, London, UK
    Microvasc Res 69:56-63. 2005
  10. ncbi request reprint A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins
    J Blake Marriott
    Division of Oncology, St George s Hospital Medical School, Tooting, London SW17 0RE, United Kingdom
    Cancer Res 63:593-9. 2003

Detail Information

Publications15

  1. ncbi request reprint Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
    Keith Dredge
    Division of Oncology, Department of Oncology, Gastroenterology, Endocrinology, and Metabolism, St George s Hospital Medical School, Cranmer Terrace, Tooting, London, United Kingdom SW17 0RE
    J Immunol 168:4914-9. 2002
    ....
  2. ncbi request reprint Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, U K
    Cancer Immunol Immunother 51:521-31. 2002
    ..Therefore, the use of Th1-inducing adjuvants may provide an essential strategy for the future success of immunotherapy...
  3. ncbi request reprint Recent developments in antiangiogenic therapy
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Jenner Wing, Cranmer Terrace, Tooting SW17 0RE, London, UK
    Expert Opin Biol Ther 2:953-66. 2002
    ..However, while potential benefits are profound, limitations of antiangiogenic therapy have also been identified, suggesting that there is also a need for caution in applying these compounds to the clinical setting...
  4. ncbi request reprint Immunological effects of thalidomide and its chemical and functional analogs
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, Cranmer Terrace, London, UK SW17 ORE
    Crit Rev Immunol 22:425-37. 2002
    ..Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties...
  5. ncbi request reprint Thalidomide analogs as emerging anti-cancer drugs
    Keith Dredge
    Division of Oncology, St George s Hospital Medical School, London, UK
    Anticancer Drugs 14:331-5. 2003
    ..The enhanced efficacy and lower side-effect profiles of the analogs in comparison to thalidomide make the use of these agents very attractive as novel anti-cancer agents...
  6. ncbi request reprint Angiogenesis inhibitors in cancer therapy
    Keith Dredge
    Division of Oncology, Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Tooting, London, SW17 0RE, UK
    Curr Opin Investig Drugs 4:667-74. 2003
    ..Elucidating the mechanisms of action will enable their use in conjunction with existing/other novel therapies, thereby maximizing the potential efficacy of angiogenesis inhibitors to fulfill their promise in patients with cancer...
  7. ncbi request reprint Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents
    J Blake Marriott
    Division of Oncology, Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London, UK
    Curr Drug Targets Immune Endocr Metabol Disord 3:181-6. 2003
    ..We will describe the various clinical studies of lead compounds that are in progress and speculate as to the potential and future development of these exciting compounds...
  8. doi request reprint The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
    Christine Galustian
    Department of Oncology, St Georges University of London, Cranmer Terrace, Tooting, London, UK
    Cancer Immunol Immunother 58:1033-45. 2009
    ..In conclusion, our data provide one explanation for adjuvant properties of lenalidomide and pomalidomide and suggest that they may help overcome an important barrier to tumour-specific immunity in cancer patients...
  9. ncbi request reprint Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
    Keith Dredge
    Department of Cellular and Molecular Medicine, St George s Hospital Medical School, London, UK
    Microvasc Res 69:56-63. 2005
    ..These data further support the use of lenalidomide as an orally administered drug for the effective treatment of angiogenesis-dependent conditions, including cancer, and suggest a potential mechanism of action...
  10. ncbi request reprint A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins
    J Blake Marriott
    Division of Oncology, St George s Hospital Medical School, Tooting, London SW17 0RE, United Kingdom
    Cancer Res 63:593-9. 2003
    ..This effect appears to be mediated via alterations in the expression of bcl-2 family proteins...
  11. ncbi request reprint The evolution of thalidomide and its IMiD derivatives as anticancer agents
    J Blake Bartlett
    Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, USA
    Nat Rev Cancer 4:314-22. 2004
  12. ncbi request reprint AE-941 (AEterna)
    Keith Dredge
    Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia
    Curr Opin Investig Drugs 5:668-77. 2004
    ....
  13. ncbi request reprint CC-1088 Celgene
    Keith Dredge
    Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia
    Curr Opin Investig Drugs 6:513-7. 2005
    ..By April 2005, however, the company was no longer developing CC-1088, with CC-10004 presumed to be the preferred compound...
  14. ncbi request reprint PI-88 and novel heparan sulfate mimetics inhibit angiogenesis
    Vito Ferro
    Drug Design Group, Progen, Pharmaceuticals Ltd, Toowong, Queensland 4066, Australia
    Semin Thromb Hemost 33:557-68. 2007
    ..The current data support the development of HS mimetics as potent antiangiogenic anticancer agents...
  15. ncbi request reprint Dendritic cell immunotherapy for melanoma
    Judy C Peng
    Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia
    Rev Recent Clin Trials 1:87-102. 2006
    ....